评论“ApoE 靶向疗法快速清除β-淀粉样蛋白并逆转 AD 小鼠模型的缺陷”。
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
机构信息
Department of Neurobiology, University of Chicago, Chicago, IL 60637, USA.
出版信息
Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.
PMID:23704555
Abstract
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis.
摘要
克莱默等人（2012 年 3 月 23 日，第 1503 页；在线发表于 2012 年 2 月 9 日）报道，倍他罗汀能迅速降低阿尔茨海默病（AD）中β-淀粉样蛋白（Aβ）沉积的两种小鼠模型中的 Aβ 水平和斑块负担。我们现在报告称，尽管倍他罗汀能降低其中一种小鼠模型中的可溶性 Aβ40 水平，但该药物对表现出 Aβ 淀粉样变性的三个品系的斑块负担没有影响。
Zotero 插件